Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis…

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 24,623 followers.

Encouraging efficacy of a comprehensive therapy consisting of sintilimab bevacizumab biosimilar IBI305 hypo-fractionated intensity-modulated radiotherapy & oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: https://t.co/3eM21ffvDg ht

26 Nov 2022

Reply Repost Favourite

New research: Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma:… https://t.

23 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.